BiotechTube
RxBio

RxBio

Johnson City, United States· Est.
rxbio.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $12.5M

Overview

RxBio is a private, preclinical-stage biotech firm specializing in vaccines and therapeutics for infectious diseases and biodefense. The company leverages its proprietary technology platform to develop medical countermeasures against high-consequence threats. While currently pre-revenue, its work is strategically aligned with government funding priorities for pandemic preparedness and national security. The company's progress is somewhat opaque due to limited public disclosure, with its website currently under maintenance.

Infectious DiseaseBiodefense

Technology Platform

Proprietary platform for developing medical countermeasures and vaccines against infectious diseases and biothreats; specific technology not publicly disclosed.

Funding History

2
Total raised:$12.5M
Series A$12M
Grant$500K

Opportunities

The global focus on pandemic preparedness and biodefense has led to increased and sustained government funding from agencies like BARDA and the DoD.
RxBio's long-standing focus positions it to compete for contracts targeting next-generation medical countermeasures.
The company's platform technology could potentially be applied to a range of high-consequence pathogens, creating multiple shots on goal.

Risk Factors

RxBio is highly dependent on the cyclical and political nature of U.S.
government biodefense funding.
The company faces significant technical and regulatory hurdles in advancing products, particularly under the FDA's Animal Rule.
A lack of public information on pipeline progress and leadership creates opacity, increasing investment and partnership risk.

Competitive Landscape

RxBio competes in a niche but competitive field against established biodefense contractors like Emergent BioSolutions and biotechnology firms with government business units. It also faces competition from academic research centers and large pharma companies that engage in infectious disease R&D. Success requires demonstrating superior platform technology and securing key government contracts.

More companies in Biologics / Biosimilars →More companies in United States →